Letter to the Editor
Delayed oral toxicity from long-term vemurafenib therapy
A. Lloyd-Lavery,
Corresponding Author
A. Lloyd-Lavery
Department of Dermatology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author T. Hodgson,
T. Hodgson
Department of Oral Medicine, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust, London, U.K.
Search for more papers by this author N. Coupe,
N. Coupe
Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author S. Bond,
S. Bond
Department of Oral Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, U.K.
Search for more papers by this author K. Shah,
K. Shah
Department of Histopathology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, U.K.
Search for more papers by this author O. Espinosa,
O. Espinosa
Department of Histopathology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, U.K.
Search for more papers by this author M.J. Payne,
M.J. Payne
Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author M.R. Middleton,
M.R. Middleton
Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author R.N. Matin,
R.N. Matin
Department of Dermatology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author
A. Lloyd-Lavery,
Corresponding Author
A. Lloyd-Lavery
Department of Dermatology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author T. Hodgson,
T. Hodgson
Department of Oral Medicine, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust, London, U.K.
Search for more papers by this author N. Coupe,
N. Coupe
Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author S. Bond,
S. Bond
Department of Oral Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, U.K.
Search for more papers by this author K. Shah,
K. Shah
Department of Histopathology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, U.K.
Search for more papers by this author O. Espinosa,
O. Espinosa
Department of Histopathology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, U.K.
Search for more papers by this author M.J. Payne,
M.J. Payne
Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author M.R. Middleton,
M.R. Middleton
Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author R.N. Matin,
R.N. Matin
Department of Dermatology, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE U.K.
Search for more papers by this author
First published: 08 February 2016
No abstract is available for this article.
References
- 1Vigarios E, Lamant L, Delord JP et al. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors. Br J Dermatol 2015; 172: 1680–2.
- 2Mangold AR, Bryce A, Sekulic A. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. J Am Acad Dermatol 2014; 71: 205–6.
- 3Larkin J, Del Vecchio M, Ascierto PA et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open label, multicentre, safety study. Lancet Oncol 2014; 15: 436–44.
- 4Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207–15.
